You are here: Industry Insights > Pharma in China

Pharma in China

Methodology Validation in Chinese Pharmacopoeia 2025: How to Report Accuracy and Precision Xing Xing
September 12, 2025
The Chinese Pharmacopoeia 2025 has introduced significant revisions to the 9101 Guidelines for Validation of Analytical Methods further promoting the application of statistics in analytical method validation.
Green Transformation of the Pharmaceutical Industry: Can Continuous Manufacturing Outperform Traditional Production? Aiden
September 05, 2025
Assesses continuous manufacturing (CM) in pharma green transition, comparing efficiency gains with traditional production amid tech/regulatory barriers and ESG impacts.
Made-in-China New Drugs: The Game and Breakthrough in the Over - 4 - Billion Market Lezhi
September 05, 2025
Profiles 16 China-made blockbuster drugs exceeding ¥1B sales, highlighting intense PD-1 competition, EGFR tech innovation, and bispecific antibody/non-oncology surge.
Made-in-China New Drugs: Breaking Through the RMB 4-Billion Battlefield lezhi
September 05, 2025
In 2024, the "Billion-Yuan Club" of made-in-China first-in-class new drugs expanded to 16 members.
Green Transformation of the Pharmaceutical Industry: Can Continuous Manufacturing Outpace Traditional Production? Aiden
September 05, 2025
In recent years, the green transformation of the pharmaceutical industry has become a widely discussed topic, with continuous manufacturing emerging as one of the key technologies driving this shift.
A Brief Overview of Emerging Target: STEAP Xiaobin
July 11, 2025
As the "low-hanging fruit" in drug discovery becomes increasingly scarce, pharmaceutical companies are shifting their focus toward novel targets. At this year's AACR Annual Meeting, AstraZeneca unveiled preclinical data for AZD0516, a drug candidate targe
2025 Q1: Oncology Business Competition Among MNCs Xiaobin
June 04, 2025
How did MNCs fare in the oncology field during Q1 of this year?
Comparison of Improved New Drugs Paths between China and the United States and Analysis of R&D Status in China Kevin
April 28, 2025
This article describes successful practices from the United States 505(b)(2) pathway and analyzes R&D status of China's modified new drugs.
Taking Over the "King of Medicine"? Chinese Enterprises Lead the Development of PD-(L)1/VEGF Bispecific Antibody Antitumor Drug Kevin
April 28, 2025
PD-(L)1 and VEGF (vascular endothelial growth factor) bispecific antibody therapies are considered a key direction for future tumor treatments, attracting increasing global interest due to their unique mechanism of action and promising clinical data.
Another BlockBuster in HKEX18A Biotech Companies: IPO of DualityBio in Hong Kong, Introducing New Capital Engine in the ADC Field? Kevin
April 15, 2025
On April 15, DualityBio, a rising star in the ADC field, was officially listed on the HKEX, marking one of the most high-profile IPOs in recent years in Chapter 18A Biotech Companies.